Sarepta Therapeutics. has filed a patent for oligonucleotides, peptides, and peptide-oligonucleotide-conjugates. The patent also covers methods of treating muscle diseases, viral infections, and bacterial infections by administering these compounds to patients in need. GlobalData’s report on Sarepta Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Sarepta Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Sarepta Therapeutics, siRNA gene silencing was a key innovation area identified from patents. Sarepta Therapeutics's grant share as of September 2023 was 39%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of muscle, viral, or bacterial infections using oligonucleotides and peptides

Source: United States Patent and Trademark Office (USPTO). Credit: Sarepta Therapeutics Inc

A recently filed patent (Publication Number: US20230310625A1) describes a peptide-oligonucleotide-conjugate for the treatment of Duchenne muscular dystrophy (DMD). The patent claims a specific formula for the conjugate, as well as various modifications and variations.

The patent claims a peptide-oligonucleotide-conjugate of Formula (I) as a potential treatment for DMD. The conjugate consists of a peptide and an oligonucleotide, which are chemically linked together. The patent also includes variations of the conjugate, such as different substitutions and modifications.

The patent further specifies the possible variations of the peptide-oligonucleotide-conjugate. These variations include different options for the peptide component, such as different amino acid sequences and modifications. The patent also describes various options for the oligonucleotide component, including different nucleobases and modifications.

Additionally, the patent provides specific ranges for the length of the oligonucleotide component. The patent claims that the length of the oligonucleotide can range from 8 to 25 nucleobases, with specific preferred ranges of 10-20 and 17-21 nucleobases.

The patent also mentions a method of treating DMD using the peptide-oligonucleotide-conjugate. The method involves administering the conjugate to a subject in need of DMD treatment. The patent does not provide specific details about the administration route or dosage.

Overall, this patent describes a peptide-oligonucleotide-conjugate and its variations as potential treatments for DMD. The patent claims a specific formula for the conjugate, as well as various modifications and variations. The method of treating DMD using the conjugate is also mentioned. However, further research and development would be needed to determine the efficacy and safety of this potential treatment.

To know more about GlobalData’s detailed insights on Sarepta Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies